Cutia Therapeutics (HKSE:02487) FCF Margin % : -585.83% (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cutia Therapeutics's Free Cash Flow for the six months ended in Jun. 2023 was HK$-220.1 Mil. Cutia Therapeutics's Revenue for the six months ended in Jun. 2023 was HK$37.6 Mil. Therefore, Cutia Therapeutics's FCF Margin % for the quarter that ended in Jun. 2023 was -585.83%.

As of today, Cutia Therapeutics's current FCF Yield % is -21.76%.

The historical rank and industry rank for Cutia Therapeutics's FCF Margin % or its related term are showing as below:

HKSE:02487' s FCF Margin % Range Over the Past 10 Years
Min: -9116.75 Med: -6192.59 Max: -305.89
Current: -305.89

During the past 3 years, the highest FCF Margin % of Cutia Therapeutics was -305.89%. The lowest was -9116.75%. And the median was -6192.59%.

HKSE:02487's FCF Margin % is ranked worse than
60.31% of 1043 companies
in the Biotechnology industry
Industry Median: -139.31 vs HKSE:02487: -305.89

Cutia Therapeutics FCF Margin % Historical Data

The historical data trend for Cutia Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics FCF Margin % Chart

Cutia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

-9,116.75

-3,268.43

Cutia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	-	-23,753.05	-2,010.32	-585.83	-

Competitive Comparison of Cutia Therapeutics's FCF Margin %

For the Biotechnology subindustry, Cutia Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cutia Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's FCF Margin % falls into.

Cutia Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cutia Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-414.862	/	12.693
	=	-3,268.43 %

Cutia Therapeutics's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-220.062	/	37.564
	=	-585.83 %

Cutia Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics (HKSE:02487) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070

Website

https://www.cutiatx.com

Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.

Executives

Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hsg Holding Limited	2201 Interest of corporation controlled by you
Ma Yun	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Aurora Cutis Limited	2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines